GI
RCUS icon

GAMMA Investing’s Arcus Biosciences RCUS Stock Holding History

GAMMA Investing’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$125K Buy
4,855
+889
+22% +$25.1K ﹤0.01% 1693
2026
Q2 		$122K Buy
3,966
+359
+10% +$8.87K ﹤0.01% 1660
2026
Q1 		$77.9K Buy
3,607
+377
+12% +$8.14K ﹤0.01% 1847
2025
Q4 		$77K Buy
3,230
+482
+18% +$9.83K ﹤0.01% 1768
2025
Q3 		$37.4K Buy
2,748
+1,021
+59% +$10.6K ﹤0.01% 2174
2025
Q2 		$14.1K Sell
1,727
-384
-18% -$3.28K ﹤0.01% 2641
2025
Q1 		$16.6K Buy
2,111
+1,006
+91% +$11.7K ﹤0.01% 2495
2024
Q4 		$16.5K Sell
1,105
-73
-6% -$1.19K ﹤0.01% 2371
2024
Q3 		$18K Buy
1,178
+12
+1% +$189 ﹤0.01% 2169
2024
Q2 		$17.8K Sell
1,166
-1,261
-52% -$20.4K ﹤0.01% 1927
2024
Q1 		$45.8K Buy
2,427
+826
+52% +$14.3K 0.01% 1102
2023
Q4 		$24.2K Buy
+1,601
New +$25.6K 0.01% 1365

Other funds holding RCUS

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GAMMA Investing's RCUS Position: Q3 2026 in Review

GAMMA Investing increased its Arcus Biosciences (RCUS) stake by 22% in Q3 2026, buying an estimated $25.1K and bringing the position to 4,855 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #1693.

GAMMA Investing first reported a position in RCUS in Q4 2023 and has held it in 12 quarters since. 7 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • GAMMA Investing held 4,855 shares of Arcus Biosciences worth $125K as of Q3 2026.
  • GAMMA Investing bought 889 Arcus Biosciences shares in Q3 2026, an estimated $25.1K.
  • Arcus Biosciences made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #1693 holding.
  • GAMMA Investing first reported a position in Arcus Biosciences in Q4 2023 and has held it in 12 quarters since.
  • 7 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.